Please Wait...

Classic Blog

How to Successfully Manage EDC Clinical Trials: Part 1

  • 0
  • 06 Oct
Does the following scenario sound familiar? You have been tasked with starting up a Phase III, 300-patient, 70-site oncology EDC clinical trial with ePRO components. New vendors are being used for both ePRO and EDC. The study is international in scope and will require diary translation. There are a few sites where telecommunications are questionable, so alternative data collection needs may be required. The study is 24 months in duration, excluding follow-up (which can last up to 5 years).
Read More

The Latest Developments in Osteoarthritis Imaging

  • 0
  • 20 Sep
I will be at the 2010 World Congress on Osteoarthritis in Brussels later this week. This conference, organized by the Osteoarthritis Research Society International (OARSI), runs from September 23 to September 29 and is a great opportunity to identify some of the new osteoarthritis imaging work that is going on in the field. Osteoarthritis (OA) is a common degenerative disease of the joints that is characterized by cartilage breakdown. It affects about 10% of adults in Western countries. Interestingly last year a work force put together by the FDA to further characterize OA defined it as a disease of the whole joint and not just focused on the cartilage.
Read More
institute of medicine (iom)

510(k) Approval Process & the Impact of Changes for Medical Devices

  • 0
  • 13 Sep

There has been a lot of discussion in the news lately about the premarket clearance process for medical devices under section 510(k) of the Federal Food and Drug Cosmetic Act. This is the approval route by which the majority of medical devices get to market by showing they are comparable to an existing marketed or approved product.

Read More

Clinical Data Collection in Oncology Studies - Most Common Challenges

  • 0
  • 08 Sep
Creating a clinical data collection strategy for oncology studies within tight timelines can be extremely challenging. Clinical data managers often face particular issues with interpreting the complexities of the study and implementing the data flow as represented in the protocol.
Read More

Modeling IVR Studies Ship Times

  • 0
  • 18 Aug
We often run into cases where an IVR (interactive voice response) system may not generate shipment orders for study kits every day. For example, commonly it seems they may only ship Monday through Thursday. In many cases this could be due to cold chain supplies having to be received immediately and being unable to guarantee that someone will be there to receive the shipment on a weekend. Others, however, may be for unrelated policy reasons. Standard modeling practice says to add a day to the shipping lead-time for every day that is not available for shipping (3 days in the case of the above example). Related to this concept, there is often some confusion for new users about whether the shipping lead-time for the IVR study refers to calendar days or business days.
Read More

Top 5 Items That Have Impacted Clinical Trial Research Technology

  • 0
  • 06 Aug
Internet: From telephone-based dial-up to cable modems to DSL to FIOS to T1 lines, the speed in which we access other computers and applications has changed the world. The Internet has changed the way we communicate, shop, play games, and access information (remember phone books?). Perhaps the largest impact to clinical trial research technology (we are now able to share data instantly); the Internet allows us to clean, review and make critical decisions earlier in the process, therefore improving clinical research. Standards: I never met anyone who thought standards were a bad idea. When zip codes were introduced in 1963, mail delivery times decreased. When CDISC CDASH standards were introduced in 2008, build time for CRFs decreased. Standards have streamlined the way we setup databases, move data around, and submit data to the FDA.
Read More
Performance Metrics Dashboard

Operational Metrics in Clinical Trials, Part 2

  • 0
  • 04 Aug
Metrics defined by the Metrics Champion Consortium (MCC), a group of experts in clinical research, define how to measure the performance of our clinical trials and makes it easy to see where we are, and where we need to be in our study. Since the metrics are the same for all clinical studies, we are comparing apples to apples. We can see the number of subjects enrolled, completed, the number of open queries and entered pages. We can see the data by study, by site, or pool site data from multiple studies. Since we are using defined metrics, we know that the definition for ‘average time from CRF submission to verification’ is: Sum (CRF Verified Date - CRF Expected Date) / (Number of CRFs). The definitions remain consistent across different clinical studies and programs.
Read More
FDA Logo

Ongoing Development of Imaging Biomarker Standards in Clinical Trials

  • 0
  • 29 Jul
One of the areas that I am active in is the ongoing development of standards for the qualification of imaging biomarkers. When the Prescription Drug User Fee Act (PDUFA) was renewed in 2007, the FDA agreed to develop by the end of 2011 a guidance document on “Imaging Standards for Endpoints in Clinical Trials.” Work on this is ongoing. At the recent FDA/RSNA/SNM meeting held on April 13-14, 2010 at the NIH, which I attended, Janet Woodcock M.D., Director of the Center for Drug Evaluation and Research (CDER) gave an update on the FDA’s perspective. A copy of her presentation can be downloaded here.
Read More
PET Neurochemical Classification

The Use of Biomarkers and PET in Early Alzheimer’s Disease Diagnosis

  • 0
  • 27 Jul
Alzheimer’s disease (AD) is the most common form of dementia and is incurable, degenerative and irreversible. It affects around 4.5 million people in the United States, a number that is expected to exceed 12 million by 2050. Neuropsychological tests, such as the mini-mental state examination (MMSE), are commonly used to diagnose patients. However, cognitive impairment may be due to another disease, not Alzheimer’s. There remains an unmet need to be able to differentiate between different forms of dementia.
Read More

Operational Metrics in Clinical Trials, Part 1

  • 0
  • 22 Jul
If you can not measure it, you can not improve it. –Lord Kelvin The Metrics Champion Consortium (MCC) develops metrics that allow trial sponsors and CROs to share a common set of clinical trial performance metrics across studies. This not-for-profit group is solving a very complex problem in a very elegant, straightforward way. They gather industry experts to identify and define a common set of clinical trial metrics that can be used in all studies. See a recent Metrics Champion Consortium press release here.
Read More

DCE-MRI Biomarkers Technology and Development

  • 0
  • 19 Jul
Following on from my recent post on Optical Coherence Tomography, another interesting medical imaging technology that I am actively involved with is Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI). DCE-MRI is an imaging technique that combines the magnetic field and radio frequency imaging of MRI with the injection into a vein of a standard MRI contrast media that makes organs, tumors and blood vessels easier to see. Essentially DCE-MRI provides the tracking of low molecular weight contrast agents through blood vessels, in particular the vasculature of tumors. By analyzing the pharmacokinetics of the contrast agent into a specific tumor, it is possible to measure alterations in vascular permeability, blood flow and extracellular volumes. This is of interest in the development of cancer drugs that inhibit new blood vessel formation (anti-angiogenesis) or disrupt existing blood vessels (vascular disrupting agents) for example. O’Connor et al in the British Journal of Cancer provides a good review of DCE-MRI imaging biomarkers in oncology clinical trials.
Read More

Imaging Biomarkers in Oncology Clinical Trials

  • 0
  • 15 Jul

Following on in my series of blog posts about imaging biomarkers and the recent BioClinica symposium, I wanted to share some insights provided by Ali Guermazi, MD (a consultant to BioClinica, who was also a co-author on the Cheson Criteria) from Boston University School of Medicine who spoke on “Imaging Biomarkers in Oncology from RECIST to beyond.”

Read More

Pages

Prompt Site Payments Key to Site Engagement

  • 0
  • 05 Feb

When it comes to achieving success in clinical trials, it truly takes a team. Sponsors, investigative sites and patients must work in partnership to complete this important work. However, with weighty matters in the clinical development process - shrinking pipelines, shortened patent life, patient population considerations, global safety standards, and the list goes on - the needs of investigative sites can be overshadowed.

Read More
CDISC

CDISC Public Courses in Audubon, March 2-12: Register with CDISC today!

  • 0
  • 04 Feb

Here's a great opportunity to learn CDISC from CDISC at Public Courses being held in Audubon, Pennsylvania at Bioclinica's eHealth Headquarters on March 2-12. (Other dates and locations are available).

Why take CDISC Training?

Read More

Necessity and Associated Benefits of Having Post-Approval Specific Technology

  • 0
  • 26 Jan

Over the last decade, across the globe, the regulatory landscape has changed considerably, with greater focus and awareness on pharmaceutical products post-approval. Legislation, coupled with public concerns about the safety of marketed drugs and the need to evaluate safety and effectiveness of the marketed products in a real-world setting is forcing many companies to embark on post-approval research.

Read More

Bioclinica Demonstrates EHR to CDASH (E2C) Standard

  • 0
  • 06 Jan

Ever since the US FDA introduced Meaningful Use requirements calling for medical practices to begin using EHR systems, the race was on to find a way to pull the data from EHR systems into the EDC systems electronically.  Many options have been tried − most focused on accessing the data from the EHR in the native HL7 format.  While this solution works, it's not easy to do. One of the stumbling blocks is the inability of site personnel to access this type of data from their EHR.

Read More

Pages

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

Great advice from our Dir. Cardiovascular Imaging on quality imaging acquisitions & assessments in clin trials. https://t.co/OVH7pZ3SL0
bioclinica (42 minutes ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will give a… https://t.co/8ymd2Q9KcJ
bioclinica (52 minutes ago)
Almost here! #PCTrials Pre-arrange a meeting w @bioclinica Drop by & s/w David Kiger & Mike Lange. Mike will giv… https://t.co/MpxTDV1T1L
bioclinica (54 minutes ago)
RT @bioclinica: Keeping to timelines in #clinicaltrials is key but can be hard to achieve. Join Bioclinica's Justin Hunt a webinar Nov. 2…
bioclinica (57 minutes ago)
RT @Xtalks: Removing Risk from #ClinicalTrial Management System (CTMS) Implementations @bioclinica https://t.co/EfuSVMSL13
bioclinica (7 hours ago)
Our Research Dev. Director Marieke Cajal in a poster presentation at #CNS Summit showed, "How to Scale up Recruitme… https://t.co/ySQpGIjvt9
bioclinica (7 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices